Psilocybin alcohol use disorder research has become an increasingly important area of addiction science as researchers investigate whether psilocybin-assisted therapy could help reduce heavy drinking, support abstinence, or improve motivation for change. Several clinical trials have produced promising results, including a well-known randomized study showing fewer heavy drinking days after psilocybin-assisted psychotherapy.
At the same time, the newer evidence is not uniformly positive. A 2025 phase 2 trial found no significant relapse-prevention benefit from a single psilocybin dose plus brief psychotherapy, while a 2026 open-label extension found that some early improvements in drinking behavior were not sustained over several months. A 2026 systematic review and meta-analysis therefore described the overall evidence as promising but mixed.
Direct answer: Current research suggests that psilocybin-assisted therapy may reduce alcohol consumption and improve abstinence outcomes in some people with alcohol use disorder, especially when combined with structured psychotherapy. However, findings vary across trials, psilocybin is not an approved AUD treatment, and larger controlled studies are needed to determine who benefits, how durable the effects are, and what treatment model works best.
Psilocybin Alcohol Use Disorder Research: What Do Studies Show?
Research on psilocybin and alcohol use disorder includes randomized clinical trials, feasibility studies, open-label extensions, and systematic reviews. The field is still relatively small, but it is large enough to reveal an important pattern: some studies show meaningful reductions in drinking, while others show smaller or less durable effects.
The strongest positive evidence comes from trials in which psilocybin was embedded within a structured psychotherapy program rather than used as a stand-alone drug. This distinction matters because the psychological support, preparation, and follow-up may contribute substantially to outcomes.
A 2026 systematic review of psilocybin-assisted psychotherapy for substance use disorders concluded that the intervention is promising but should be understood as a complex treatment involving pharmacology, psychotherapy, subjective experience, and context rather than as a medication acting alone.
What Is Alcohol Use Disorder?
Alcohol use disorder, or AUD, is a medical condition characterized by difficulty controlling alcohol use despite negative consequences. Severity can range from mild to severe.
AUD may involve:
- Drinking more or longer than intended
- Repeated unsuccessful efforts to cut down
- Strong cravings
- Spending substantial time drinking or recovering
- Continued use despite relationship, work, or health problems
- Tolerance
- Withdrawal symptoms
- Giving up important activities
- Using alcohol in risky situations
AUD is not simply a matter of willpower. It involves behavioral, psychological, social, and biological factors and can vary greatly from person to person.
How Is Alcohol Use Disorder Usually Treated?
Evidence-based treatment for AUD can include psychotherapy, behavioral support, mutual-help programs, medications, or combinations of these approaches.
Behavioral Therapies
Cognitive behavioral therapy, motivational enhancement therapy, contingency management, and other structured approaches can help people identify triggers, develop coping strategies, strengthen motivation, and reduce relapse risk.
Medications
FDA-approved medications for alcohol use disorder include naltrexone, acamprosate, and disulfiram. These medications work through different mechanisms and are not appropriate for every person.
Because many people continue to struggle despite existing options, researchers are exploring whether psychedelic-assisted therapy could provide an additional pathway for selected patients.
What Did the 2022 Psilocybin Alcohol Trial Find?
A landmark randomized clinical trial published in 2022 enrolled 93 adults with alcohol use disorder. Participants received psychotherapy and were randomly assigned to either two psilocybin sessions or an active placebo.
The psilocybin group had a significantly lower percentage of heavy drinking days during the 32-week follow-up period than the active-placebo group. The trial became one of the strongest pieces of evidence supporting further research into psilocybin and alcohol use disorder.
Importantly, the treatment included substantial psychotherapy. The study therefore tested psilocybin-assisted psychotherapy, not psilocybin in isolation.
What Did the 2025 Relapse-Prevention Trial Find?
A 2025 phase 2 randomized clinical trial in Switzerland tested whether a single psilocybin session combined with brief psychotherapy could reduce relapse after alcohol withdrawal treatment.
The study did not find significant differences between psilocybin and placebo in abstinence duration or average alcohol use at four weeks or six months. Participants in both groups reported reduced craving, with some additional craving reduction in the psilocybin group.
This study is important because it demonstrates that positive psychedelic results are not automatic. Treatment intensity, number of sessions, participant characteristics, timing, and psychotherapy model may all influence outcomes.
What Did the 2025 AUD and Depression Trial Find?
A separate 2025 randomized feasibility trial studied people with alcohol use disorder and comorbid depressive symptoms. Participants received either two standard psilocybin sessions or very-low-dose psilocybin alongside usual care.
At twelve weeks, the standard-dose group showed a higher abstinence rate, fewer drinking days, and lower craving frequency than the control group. The researchers concluded that the approach appeared feasible and acceptable, while noting the small sample size and challenges with maintaining blinding.
The study also highlights an important real-world issue: alcohol use disorder frequently overlaps with depression and other psychiatric symptoms, making it difficult to separate one treatment effect from another.
What Did the 2026 Meta-Analysis Find?
A 2026 systematic review and meta-analysis evaluated available psilocybin-assisted therapy studies for alcohol use disorder. The analysis found significant within-group reductions across several drinking outcomes and moderate short-term advantages compared with control groups.
The review also found higher odds of maintaining abstinence among psilocybin-treated participants. However, not every drinking measure remained significantly better at longer follow-up.
The authors summarized the evidence as mixed but suggestive of preliminary efficacy. That is currently one of the most accurate ways to describe the state of the science.
What Did the 2026 Open-Label Extension Find?
A 2026 open-label extension followed 59 adults from an earlier phase II alcohol use disorder trial. All participants received a supervised psilocybin administration with manualized therapy.
Among participants who entered the extension with higher drinking intensity, heavy drinking days and other drinking measures improved at one month but later returned toward entry levels. Craving, abstinence self-efficacy, and treatment readiness improved shortly after the session, but their trajectories varied over time.
These findings reinforce an important point: early improvement does not always equal durable recovery. Long-term outcomes remain one of the biggest unanswered questions in psilocybin AUD research.
How Might Psilocybin Affect Alcohol Use Disorder?
Researchers are investigating several mechanisms that may help explain why psilocybin and alcohol use disorder outcomes sometimes improve together.
Serotonin 5-HT2A Receptor Signaling
Psilocybin is converted into psilocin, which interacts strongly with serotonin receptors, especially the 5-HT2A receptor. This activity can influence perception, cognition, emotion, and communication among brain networks.
Our article on psilocybin vs. psilocin explains this pharmacology in more detail.
Craving and Motivation
Several studies have reported short-term reductions in alcohol craving and increases in motivation, readiness for change, or confidence in abstinence. These effects may be clinically important, but they are not consistent enough to be treated as guaranteed outcomes.
Cognitive Flexibility
Addiction can involve entrenched habits, rigid expectations, and repeated cue-response patterns. Psilocybin may temporarily increase cognitive flexibility, potentially allowing people to reconsider habitual beliefs or behaviors during psychotherapy.
Emotional Processing
Some people with AUD drink partly in response to stress, trauma, depression, shame, or other difficult emotional states. Psychedelic-assisted psychotherapy may change how emotional material is processed, although this mechanism remains under investigation.
Brain-Network Changes
Psilocybin alters communication within and between large-scale brain networks. Researchers are studying whether reduced rigidity in these systems could support behavior change. Mindwell’s article on the Default Mode Network explores this topic in more detail.
What Role Does Psychotherapy Play?
Psychotherapy appears to be a major part of the treatment model studied in psilocybin and alcohol use disorder research.
Most clinical protocols include:
- Preparation before dosing
- Motivational or cognitive behavioral therapy
- Supervised psilocybin sessions
- Post-session processing or integration
- Ongoing follow-up
- Monitoring of alcohol use and craving
A 2026 systematic review emphasized that psilocybin-assisted treatment for substance use disorders should be viewed as a complex intervention rather than a simple pharmacological treatment.
Can Psilocybin Reduce Alcohol Cravings?
Some studies have reported reductions in alcohol craving after psilocybin-assisted therapy. The 2025 relapse-prevention trial found craving reductions in both treatment groups, with an additional decrease in the psilocybin group. The 2026 open-label extension also reported short-term craving improvements.
However, craving reduction is not universal or always sustained. Craving is only one part of AUD, and reduced craving does not necessarily guarantee long-term abstinence.
Can Psilocybin Prevent Alcohol Relapse?
The answer is not yet clear.
Some studies report improved abstinence or reduced heavy drinking, while the 2025 Swiss relapse-prevention trial did not find a significant advantage for a single psilocybin session over placebo.
These mixed findings suggest that relapse prevention may depend on multiple factors, including the number of psilocybin sessions, psychotherapy intensity, AUD severity, recent detoxification, comorbid conditions, and ongoing support.
Psilocybin, Alcohol Use Disorder, and Depression
Depression frequently co-occurs with alcohol use disorder. This overlap matters because improvements in mood could potentially influence drinking behavior, while reduced alcohol use could also improve mood.
The 2025 feasibility trial specifically studied people with both AUD and depressive symptoms. Mindwell’s article on psilocybin and depression examines the depression literature separately.
Can Psilocybin Be Risky for People With AUD?
Yes. Psilocybin is not risk-free, and alcohol use disorder can introduce additional medical and psychiatric considerations.
Potential concerns include:
- Acute anxiety or panic
- Confusion or impaired judgment
- Temporary increases in blood pressure or heart rate
- Medication interactions
- Co-occurring psychiatric conditions
- Medical complications associated with alcohol use
- Alcohol withdrawal risk
Alcohol withdrawal can be medically dangerous and, in severe cases, life-threatening. Psilocybin should never be treated as a substitute for appropriate medical withdrawal management.
Why Alcohol Withdrawal Is a Separate Medical Issue
Alcohol withdrawal can include tremor, sweating, agitation, nausea, seizures, hallucinations, and delirium tremens. Severe withdrawal requires medical assessment and may require supervised treatment.
Clinical psilocybin studies involving AUD typically screen participants carefully and often enroll people after withdrawal has already been medically managed.
This distinction is essential: psychedelic-assisted therapy is being studied as a potential treatment for ongoing alcohol use disorder, not as a treatment for acute alcohol withdrawal.
Is Psilocybin Approved for Alcohol Use Disorder?
No. Psilocybin is not FDA-approved for alcohol use disorder.
Established treatments include evidence-based psychotherapy, behavioral support, and approved medications. Psilocybin-assisted therapy remains experimental and should be described as such.
How Does Psilocybin AUD Research Connect With Tolerance?
People sometimes confuse alcohol tolerance with psychedelic tolerance, but they are different processes involving different pharmacological systems.
Mindwell’s guide to psilocybin tolerance explains how repeated serotonergic psychedelic exposure can temporarily reduce sensitivity through receptor adaptation.
What Are the Main Limitations of Psilocybin AUD Research?
The current evidence has several important limitations:
- Relatively small clinical samples
- Different psychotherapy models between studies
- Different numbers of psilocybin sessions
- Difficulty maintaining blinding
- Variation in AUD severity and treatment history
- Limited long-term follow-up
- High expectancy effects
- Mixed results across trials
- Uncertainty about which patients are most likely to benefit
These limitations explain why larger, multicenter randomized trials are still needed.
Common Misconceptions About Psilocybin and Alcohol Use Disorder
Myth: Psilocybin has been proven to cure alcoholism.
Reality: No. The research is promising but mixed, and psilocybin is not an approved cure or treatment.
Myth: One psilocybin session reliably prevents relapse.
Reality: A 2025 randomized trial did not find a significant relapse-prevention benefit from a single session.
Myth: Psilocybin works without therapy.
Reality: Most positive AUD trials studied psilocybin as part of a structured psychotherapy program.
Myth: Reduced craving guarantees abstinence.
Reality: Craving is only one component of alcohol use disorder, and short-term craving reduction may not persist.
Myth: Psilocybin can treat alcohol withdrawal.
Reality: Acute alcohol withdrawal is a medical condition and may require supervised treatment. Psilocybin is not a withdrawal treatment.
Frequently Asked Questions
Current research suggests that psilocybin-assisted therapy may help reduce alcohol consumption and support abstinence in some people with alcohol use disorder, but results are mixed and the evidence base remains limited. Larger controlled studies are still needed.
No. Psilocybin is not an FDA-approved treatment for alcohol use disorder. Its use for AUD remains experimental and is being studied in controlled clinical research.
A 2022 randomized clinical trial found that people receiving psilocybin-assisted psychotherapy had a lower percentage of heavy drinking days than those receiving active placebo plus psychotherapy over the follow-up period.
A 2026 systematic review and meta-analysis found preliminary evidence that psilocybin-assisted therapy may reduce several drinking outcomes and increase the odds of abstinence, while also concluding that the overall evidence remains mixed.
No. A 2025 phase 2 trial found that a single psilocybin dose plus brief psychotherapy did not significantly improve relapse prevention compared with placebo in a small sample. A 2026 open-label extension also found that some early drinking improvements were not sustained.
Researchers are studying several possible mechanisms, including serotonin 5-HT2A receptor signaling, changes in craving, cognitive flexibility, emotional processing, motivation, self-efficacy, and interactions with psychotherapy.
No. Current evidence does not support replacing established alcohol use disorder treatments with psilocybin. Evidence-based care can include behavioral therapies, mutual-help support, and FDA-approved medications such as naltrexone, acamprosate, and disulfiram.
No. Clinical studies typically combine psilocybin with preparation, structured psychotherapy or counseling, supervised dosing, follow-up, and formal outcome monitoring. Those elements are part of the intervention being studied.
Yes. Risks can include acute anxiety, confusion, increases in blood pressure, impaired judgment, medication interactions, and complications related to alcohol withdrawal or other medical conditions. Clinical studies use screening and monitoring to reduce these risks.
Not reliably. Some studies have reported reductions in craving after psilocybin-assisted therapy, but results vary and improvements may not persist. Psilocybin should not be described as a guaranteed craving treatment.
What Current Research Tells Us About Psilocybin and Alcohol Use Disorder
Psilocybin alcohol use disorder research has moved beyond early pilot studies into randomized trials, meta-analyses, and longer follow-up studies. Some of the findings are genuinely encouraging: reduced heavy drinking, higher abstinence rates, lower craving, and improved treatment motivation have all been reported.
At the same time, the results are not uniform. Some trials have failed to show significant relapse-prevention benefits, and newer follow-up data suggest that certain early gains may fade over time. The most recent systematic reviews therefore describe psilocybin-assisted therapy as promising rather than proven.
The most accurate conclusion is balanced: psilocybin-assisted therapy may become a useful future treatment option for some people with alcohol use disorder, especially when embedded in structured psychotherapy, but larger controlled trials are needed to determine efficacy, durability, safety, and which patients are most likely to benefit.
Research References
2026 systematic review and meta-analysis of psilocybin-assisted therapy for alcohol use disorder
2026 open-label extension of a phase II randomized trial of psilocybin-assisted therapy for AUD












